Please Wait a Moment
X

Articles

27Jul

Bio-Rad Geenius HIV 1/2 Implementation

27 Jul, 2020 | Return|

CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.

Read all about it on the Communication page by clicking this link: Communications

 

 

Related

World Patient Safety Day 2020

The COVID-19 pandemic has unveiled the huge challenges and risks health workers are facing globally ...

Read More >

CTS to Implement Licensed Babesia testing

In response to the FDA guidance document for Babesia, CTS will implement the licensed Grifols  ...

Read More >

Confirmatory Testing Delay for HIV-1 Western Blot and HIV-2 EIA

Currently, there are limited supplies of the reagents used for HIV-1 Western Blot and HIV-2 EIA test...

Read More >

Update on CTS Implementation of the Grifols Procleix Ultrio Elite Assay

In July, all 5 CTS laboratories will convert from the current Grifols Ultrio Plus NAT triplex assay ...

Read More >

New Learning Center with New Content Launches on March 30!

A new Learning Center website will launch on Monday, March 30, 2020. While the link to the new Learn...

Read More >

CTS Testing Algorithm to be Revised on December 17, 2018

The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm. Th...

Read More >